|Articles|October 15, 2002
- BioPharm International-10-01-2002
- Volume 15
- Issue 10
FDA Launches Major CGMP Review
Author(s)Jill Wechsler
by Jill Wechsler Agency officials are reexamining manufacturing standards and plant inspection processes.
Advertisement
Articles in this issue
about 23 years ago
Process Validation: How Much to Do and When to Do Itabout 23 years ago
Biotech Will Recover!about 23 years ago
GMPs and Pharmaceutical Labelingabout 23 years ago
Revolutionizing Biologics RegulationNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
2
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
3
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
4
Achieving Real Impact Navigating the Data and Regulatory Barriers to AI Adoption in Bio/pharma
5
